Geode Capital Management LLC Boosts Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Geode Capital Management LLC grew its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 2.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,815,710 shares of the company's stock after buying an additional 42,777 shares during the period. Geode Capital Management LLC owned 1.50% of 10x Genomics worth $41,009,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. KBC Group NV lifted its holdings in 10x Genomics by 38.8% in the third quarter. KBC Group NV now owns 3,225 shares of the company's stock valued at $73,000 after buying an additional 902 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of 10x Genomics by 134.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company's stock worth $32,000 after acquiring an additional 939 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in shares of 10x Genomics by 53.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock valued at $66,000 after purchasing an additional 1,012 shares during the period. Blue Trust Inc. boosted its position in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock valued at $40,000 after purchasing an additional 1,025 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after purchasing an additional 1,265 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on TXG shares. Barclays dropped their price target on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Leerink Partners initiated coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They issued an "outperform" rating and a $35.00 price target for the company. Citigroup cut their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a "buy" rating on the stock in a research report on Wednesday, October 30th. Leerink Partnrs raised 10x Genomics to a "strong-buy" rating in a research report on Tuesday, September 3rd. Finally, Stephens reissued an "overweight" rating and set a $30.00 target price on shares of 10x Genomics in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $25.14.

10x Genomics Trading Down 0.4 %

Shares of TXG stock traded down $0.06 during trading hours on Wednesday, hitting $14.67. 902,314 shares of the company were exchanged, compared to its average volume of 1,748,773. The firm has a fifty day simple moving average of $15.23 and a 200 day simple moving average of $18.56. 10x Genomics, Inc. has a 52-week low of $12.95 and a 52-week high of $57.78. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -9.59 and a beta of 1.84.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business's revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.51) earnings per share. Sell-side analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.